A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Hafnium oxide (Primary) ; Cetuximab; Ropidoxuridine
- Indications Head and neck cancer; Hypopharyngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms NANORAY-312
- Sponsors Janssen; Johnson & Johnson Innovation; Nanobiotix
Most Recent Events
- 02 Apr 2025 According to a Nanobiotix media release, the company completed the NANORAY-312 US sponsorship transfer from Nanobiotix to Johnson & Johnson, in 4Q2024, with intent to transfer NANORAY-312 globally to Johnson & Johnson by 3Q2025.
- 02 Apr 2025 According to a Nanobiotix media release, the company aligned on intent to transfer the global NANORAY-312 sponsorship from Nanobiotix to Janssen Pharmaceutica NV, a Johnson & Johnson Company (Johnson & Johnson) in 2Q2024 to begin preparations for interim analysis.
- 17 Mar 2025 According to a Nanobiotix media release, company amendment removes Nanobiotix's funding obligation for NANORAY-312 and releases Johnson & Johnson from select future potential milestone payments, while safeguarding Nanobiotix's path to sustainable cashflow through significant potential milestone payments.